A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients with Pulmonary Sarcoidosis

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Diagnosis of pulmonary sarcoidosis with some respiratory symptoms - Must be taking stable dose of at least 7.5 mg of prednisone daily for 3 months and willing to taper dose down - Body weight between 88-352 lbs - Please contact umnsarc@umn.edu if you have any questions

Exclusion Criteria:

- Active heavy smoker (defined as > 20 cigarettes/day or e-cigarette equivalent) - Active substance abuse (drugs, alcohol, or cannabis) or history of substance abuse within the last 12 months - Pregnancy or breast-feeding

Conditions & Interventions

Conditions:
Rare Diseases, Breathing, Lung & Sleep Health, Respiratory System
Keywords:
Sarcoidosis, Clinics and Surgery Center (CSC)

More Information

Description: We are studying the use of Efzofitimod given IV at two different doses to treat people who have pulmonary sarcoidosis. Participants must be on stable treatment with an oral corticosteroid with or without immunosuppressant therapy. Some people will receive IV saline (placebo) and we will compare groups to see how well the drug works and what side effects occur. The trial will last for about one year.
Study Contact: UMN Sarcoidosis Research Group Study - umnsarc@umn.edu
Principal Investigator: Maneesh Bhargava
IRB Number: STUDY00016463